2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1873

Clinical Characteristics and Health Care Utilization Patterns Among Patients with Fibromyalgia Newly Prescribed Amitriptyline, Duloxetine, Gabapentin or Pregabalin: A Large Cohort Study
Abstract Number: 2025

Clinical Characteristics and Therapy Response in a Large Single-Centre Cohort of Patients with Periodic Fever with Aphtous Stomatitis, Pharyngitis and Cervical Adenitis Syndrome
Abstract Number: 643

Clinical Characteristics for Future Development of Systemic Lupus Erythematosus in Korean Patients with Idiopathic Thrombocytopenic Purpura
Abstract Number: 1552

Clinical Correlates, Treatment Outcomes and Predictors of Vasculitis Associated with Rheumatoid Arthritis in the ‘Biologic Era’ : A Case-Control Study
Abstract Number: 700

Clinical Correlation of Flow-Mediated Endothelium-Dependent Vasodilatation in Systemic Sclerosis
Abstract Number: 1392

Clinical Correlation with Anti Double Stranded Deoxyribonucleic Acid Via Enzyme Linked Immunoassay Versus Multiplex Immunoassay
Abstract Number: 2005

Clinical Course and Outcomes of Children with Juvenile Idiopathic Arthritis-Associated Uveitis and Idiopathic Uveitis
Abstract Number: 203

Clinical Course Factors Associated with Outcome of Monoarthritis : A Retrospective Study of 173 Cases
Abstract Number: 229

Clinical Differences Between Adult and Juvenile Dermatomyositis Associated with Anti-NXP2 Autoantibodies
Abstract Number: 2436

Clinical Effectiveness and Costs of an Integrated Rehabilitation Programme Compared with Outpatient Physiotherapy for Chronic Knee Pain
Abstract Number: 159

Clinical Efficacy Outcomes with up to 3 Years of Pegloticase Treatment for Refractory Chronic Gout
Abstract Number: 1941

Clinical Evaluation of Anti-Aminoacyl tRNA Synthetase Antibodies in Japanese Patients with Connective Tissue Diseases
Abstract Number: 1367

Clinical Features and Treatment Results of Japanese Patients with SAPHO (Synovitis-Acne-Pustulosis-Hyperostosis-Osteitis) Syndrome
Abstract Number: 1470

Clinical Features Associated with Anti-Th/to in Non-Scleroderma Patients – Sine Scleroderma?
Abstract Number: 912

Clinical Features Associated with Progression of Knee Radiographic Osteoarthritis: Data From the Osteoarthritis Initiative

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].